(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/221827 A2

(51) International Patent Classification:
A61K 39/39 (2006.01)

(21) International Application Number:
PCT/US2022/071664

(22) International Filing Date:
11 April 2022 (11.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/173,958 12 April 2021 (12.04.2021) US
63/246,740 21 September 2021 (21.09.2021) US

(71) Applicant: **CORNER THERAPEUTICS, INC.** [US/US]; 300 North Beacon Street, Building 39, Suite 202, Watertown, Massachusetts 02472 (US).

(72) Inventors: **FINN, Kelsey K**; c/o Corner Therapeutics, Inc., 300 North Beacon Street, Building 39, Suite 202, Watertown, Massachusetts 02472 (US). **CHOW, Jonathan**; c/o Corner Therapeutics, Inc., 300 North Beacon Street, Building 39, Suite 202, Watertown, Massachusetts 02472 (US). **GOSSELIN, Emily**; c/o Corner Therapeutics, Inc., 300 North Beacon Street, Building 39, Suite 202, Watertown, Massachusetts 02472 (US). **ZHIVAKI, Dania**; c/o Corner Therapeutics, Inc., 300 North Beacon Street, Building 39, Suite 202, Watertown, Massachusetts 02472 (US).

(74) Agent: **LEKUTIS, Christine** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: HYPERACTIVATORS OF MAMMALIAN DENDRITIC CELLS




FIG. 3

(57) Abstract: The present disclosure relates to lysophosphatidylcholine (LPC) compounds and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells or canine dendritic cells. The present disclosure also relates to compositions comprising a LPC and one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.

[Continued on next page]

WO 2022/221827 A2

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*